Generation of a novel factor IX with augmented clotting activities in vitro and in vivo

Hough, 2005, Gene therapy for hemophilia: an imperative to succeed, J Thromb Haemost, 3, 1195, 10.1111/j.1538-7836.2005.01401.x Mann, 1999, Biochemistry and physiology of blood coagulation, Thromb Haemost, 82, 165, 10.1055/s-0037-1615780 Chang, 2002, Identification of functionally important residues of the epidermal growth factor‐2 domain of factor IX by alanine‐scanning mutagenesis. Residues Asn(89)‐Gly(93) are critical for binding factor VIIIa, J Biol Chem, 277, 25393, 10.1074/jbc.M105432200 Celie, 2002, The connecting segment between both epidermal growth factor‐like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain, J Biol Chem, 277, 20214, 10.1074/jbc.M108446200 Bajaj, 1999, Region of factor IXa protease domain that interacts with factor VIIIa: analysis of select hemophilia B mutants, Thromb Haemost, 82, 218, 10.1055/s-0037-1615836 Kolkman, 1999, Regions 301‐303 and 333‐339 in the catalytic domain of blood coagulation factor IX are factor VIII‐interactive sites involved in stimulation of enzyme activity, Biochem J, 339, 217, 10.1042/bj3390217 Lin, 2002, Identification of functionally important residues in the protease domain of factor IX that are critical for binding factor XIa, TFPI, and antibodies, Blood, 100, 263a Chang, 1998, Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity, J Biol Chem, 273, 12089, 10.1074/jbc.273.20.12089 Griffith, 1985, Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill, J Clin Invest, 75, 4, 10.1172/JCI111694 Mathur, 1997, Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X, J Biol Chem, 272, 23418, 10.1074/jbc.272.37.23418 Bevington, 1992 Straume, 1992, Analysis of residuals: criteria for determining goodness‐of‐fit, Methods Enzymol, 210, 87, 10.1016/0076-6879(92)10007-Z Segal, 1975 Neels, 2000, Activation of factor IX zymogen results in exposure of a binding site for low‐density lipoprotein receptor‐related protein, Blood, 96, 3459, 10.1182/blood.V96.10.3459 Lin, 1997, A coagulation factor IX‐deficient mouse model for human hemophilia B, Blood, 90, 3962, 10.1182/blood.V90.10.3962 Jin, 2004, Creation of a mouse expressing defective human factor IX, Blood, 104, 1733, 10.1182/blood-2004-01-0138 Miao, 2001, Long‐term and therapeutic‐level hepatic gene expression of human factor IX after naked plasmid transfer in vivo, Mol Ther, 3, 947, 10.1006/mthe.2001.0333 Yu, 2004, TXAS‐deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate‐induced death, Blood, 104, 135, 10.1182/blood-2003-10-3661 Smith, 1985, Monoclonal antibodies to coagulation factor IX define a high‐frequency polymorphism by immunoassays, Am J Hum Genet, 37, 668 Tranholm, 2003, Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A, Blood, 102, 3615, 10.1182/blood-2003-05-1369 Xiao, 1998, Production of high‐titer recombinant adeno‐associated virus vectors in the absence of helper adenovirus, J Virol, 72, 2224, 10.1128/JVI.72.3.2224-2232.1998 Davidoff, 2005, Comparison of the ability of adeno‐associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models, Mol Ther, 11, 875, 10.1016/j.ymthe.2004.12.022 Sambrano, 2001, Role of thrombin signalling in platelets in haemostasis and thrombosis, Nature, 413, 74, 10.1038/35092573 Hamaguchi, 1994, The role of amino‐terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa, Blood, 84, 1837, 10.1182/blood.V84.6.1837.1837 Fribourg, 2006, The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation, Biochemistry, 45, 10777, 10.1021/bi060451h Frazier, 1989, Mapping of monoclonal antibodies to human factor IX, Blood, 74, 971, 10.1182/blood.V74.3.971.971 Mutucumarana, 1992, The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study, J Biol Chem, 267, 17012, 10.1016/S0021-9258(18)41886-8 Manno, 2006, Successful transduction of liver in hemophilia by AAV‐Factor IX and limitations imposed by the host immune response, Nat Med, 12, 342, 10.1038/nm1358 Manno, 2003, AAV‐mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, 101, 2963, 10.1182/blood-2002-10-3296 Gao, 2002, Novel adeno‐associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci USA, 99, 11854, 10.1073/pnas.182412299 Fay, 2004, Activation of factor VIII and mechanisms of cofactor action, Blood Rev, 18, 1, 10.1016/S0268-960X(03)00025-0 Stoilova‐McPhie, 2002, 3‐Dimensional structure of membrane‐bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3‐dimensional density map derived by electron crystallography, Blood, 99, 1215, 10.1182/blood.V99.4.1215 Brandstetter, 1995, X‐ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B, Proc Natl Acad Sci USA, 92, 9796, 10.1073/pnas.92.21.9796